Premium Reports
Contact KLAS
 Download Report    Zoom in charts

Preferences

   Bookmark

Related Series

 No Related Series

Related Segments

 End chart zoom
VIDAL (Non-US) VIDAL (Non-US)
* A page refresh may be necessary to see the updated image

VIDAL (Non-US)
First Look 2022

author - Eder Lagemann
Author
Eder Lagemann
author - Joseph Ybarra
Author
Joseph Ybarra
author - Braden Taylor
Author
Braden Taylor
 
January 7, 2022 | Read Time: 1  minute

Current Time Inside Cache Tag Helper: 8/16/2022 12:34:07 PM and Model.reportId = 2062

As the need for safe, efficient medication management becomes more critical, VIDAL plays an important role in providing drug database software to healthcare organizations outside the US that are using ePrescribing. VIDAL partners with EMR vendors worldwide to offer customers drug referencing and interaction-checking capabilities that are integrated with EMRs. VIDAL also offers their solution as a standalone product. This report shares customer perceptions of how well VIDAL improves prescription quality and optimizes medication management.

to see the full dataset.

if you don't have a login, getting started is easy.

Provider Organizations
Fill out our registration form to verify your organization.
HIT Companies
Contact a KLAS representative for plans and pricing.
Current Time Inside Cache Tag Helper: 8/16/2022 12:34:07 PM and Model.reportId = 2062

Key Findings

  1. VIDAL Customer Experience: An Initial Look
  2. KLAS’ Points to Ponder
  3. VIDAL: Company Profile at a Glance
  4. Solution Technical Specifications (provided by VIDAL)
author - Madison Moniz
Designer
Madison Moniz
author - Joel Sanchez
Project Manager
Joel Sanchez
 Download Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2022 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.